Derek Maetzold Sells 12,428 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 12,428 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $33.20, for a total value of $412,609.60. Following the transaction, the insider directly owned 21,479 shares of the company’s stock, valued at $713,102.80. This represents a 36.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 1.2%

Shares of CSTL stock traded up $0.41 during mid-day trading on Tuesday, reaching $33.44. 396,178 shares of the company’s stock traded hands, compared to its average volume of 404,443. The company’s 50-day moving average price is $27.48 and its 200-day moving average price is $25.43. The company has a market cap of $1.02 billion, a P/E ratio of -50.67 and a beta of 0.98. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The company had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. On average, equities analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Amundi boosted its stake in Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after purchasing an additional 4,111 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Castle Biosciences by 548.9% during the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after purchasing an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after buying an additional 655 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Castle Biosciences by 34.7% in the 2nd quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after buying an additional 8,992 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CSTL shares. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. BTIG Research boosted their price target on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Roth Capital initiated coverage on Castle Biosciences in a research note on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target on the stock. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Castle Biosciences has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.